PharmaCyte Biotech
PMCB
PMCB
31 hedge funds and large institutions have $2.4M invested in PharmaCyte Biotech in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
31% less capital invested
Capital invested by funds: $3.47M → $2.4M (-$1.07M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
31
Holding in Top 10
–
Calls
$18K
Puts
$4K
Top Buyers
| 1 | +$219K | |
| 2 | +$204K | |
| 3 | +$44.8K | |
| 4 |
Renaissance Technologies
New York
|
+$14.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.56K |
Top Sellers
| 1 | -$388K | |
| 2 | -$62K | |
| 3 | -$40.8K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$30.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$19.2K |